ClinicalTrials.gg
CompletedNCT02919696Updated Sep 25, 2020Results posted

A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

A Phase 1 interventional study of Abemaciclib in Advanced Cancer and Metastatic Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing abemaciclib in Neoplasm Metastasis — 3 open to participants now, 8 under way, 3 of them phase 3. abemaciclib · Neoplasm Metastasis.

Enrollment
11th of 15
26 · median 48
Started
2017
the only one that year
Phase 1
5 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
9 of 15
Eli Lilly and Company

Among the 15 studies testing abemaciclib in Neoplasm Metastasis, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 1, and was the 5th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 15 studies testing abemaciclib in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing abemaciclib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety of the study drug known as abemaciclib in native Chinese participants with advanced and/or metastatic cancers.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer

Browse trials for

Keywords

  • CDK4/6 Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must have histological or cytological evidence of cancer which is advanced and/or , and is an appropriate candidate for experimental therapy in the judgment of the investigator, after available standard therapies have ceased to provide clinical benefit.
  • Have the presence of measureable disease as defined by the (RECIST 1.1).
  • Are native Chinese men or women.
  • Have adequate organ function, including:

    • Hematologic: (ANC) ≥1.5 x 109/Liters (L), ≥100 x 109/L, and ≥9 grams per deciliter. Participants may receive erythrocyte transfusions to achieve this hemoglobin level or platelet transfusions to achieve platelet levels at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after transfusion.
    • Hepatic: ≤1.5 times (ULN), (ALT), and aspartate aminotransferase (AST) ≤3.0 times ULN.
    • Renal: Serum creatinine ≤1.2 milligrams per deciliter (mg/dL) for males or ≤1.0 mg/dL for females.
  • Have a performance status ≤1 on the (ECOG) scale.
  • Recovered from the acute effects of therapy (treatment- related toxicity resolved to baseline) except for residual alopecia.
  • Have an estimated of ≥12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Have received previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and therapy) within 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug.
  • Have an acute leukemia or other relevant cancers at the discretion of the investigator.
  • Females who are pregnant or lactating.
  • Participants consuming drugs or foods that are known to be inducers (for example, grapefruit juice, phenytoin, carbamazepine) or strong inhibitors of should be excluded during Cycle 1.
  • Have history or evidence of central nervous system (CNS) or . Screening of asymptomatic participants without history of is not required for enrollment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Abemaciclib Dose Level 1

    Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib Dose Level 2

    Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.

    Drug: Abemaciclib

Interventions

  • Administered orally

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Drug Related Adverse Events

    Number of participants with one or more drug related adverse events. Clinically significant events were defined as serious adverse events, regardless of causality. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

    Time frame: Baseline through End of Study (Up to 10 Months)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites Single Dose

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and its Metabolites following a single oral dose.

    Time frame: Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose

  2. PK: Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites (Twice Daily Dosing)

    PK: Maximum Concentration (Cmax) of Abemaciclib and its Metabolites following a twice daily dosing.

    Time frame: Cycle 1, Day(D) 31; Predose, 1, 2, 4, 6, 8, 10, 24 Hours Postdose

  3. PK: Area Under Concentration Time Curve (AUC) From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites Single Dose

    PK: Area Under Concentration Time Curve (AUC) from Time Zero to 12 hours (AUC \[0-12\]) of Abemaciclib and its Metabolites following a single oral dose.

    Time frame: Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose

  4. PK: AUC From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites (Twice Daily Dosing)

    PK: AUC from Time Zero to 12 hours (AUC \[0-12\]) of Abemaciclib and its Metabolites following twice daily dosing

    Time frame: Cycle 1, Day(D) 31; Predose, 1, 2, 4, 6, 8, 10, 24 Hours Postdose

  5. PK: AUC From Time Zero to Infinity (AUC[0-inf]) of Abemaciclib and Its Metabolites Single Dose

    PK: AUC from Time Zero to Infinity (AUC\[0-inf\]) of Abemaciclib and its Metabolites following a single oral dose.

    Time frame: Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose

  6. Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

    ORR was defined as the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum LD of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

    Time frame: Baseline to Measured Progressive Disease (Up to 13 Months )

07

Results

Posted Sep 25, 2020

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib 150 mgAbemaciclib 200 mg
Started1214
Received at least one dose of study drug1213
Pk 100 mg abemaciclib dose50
Pk 150 mg abemaciclib dose02
Death on treatment10
Progressive disease79
Completed89
Not completed45
Withdrew: Adverse event12
Withdrew: Withdrawal by subject21
Withdrew: Sponsor decision11
Withdrew: Never treated01

Outcome measures

PrimaryNumber of Participants With One or More Drug Related Adverse Events

Number of participants with one or more drug related adverse events. Clinically significant events were defined as serious adverse events, regardless of causality. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

Time frame:
Baseline through End of Study (Up to 10 Months)
Reported as:
Count of participants · Participants
Number of Participants With One or More Drug Related Adverse Events
ParticipantsAbemaciclib 150 mgAbemaciclib 200 mg
Number of Participants With One or More Drug Related Adverse Events1213
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites Single Dose

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and its Metabolites following a single oral dose.

Time frame:
Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites Single Dose
nanogram/milliliter (ng/mL)Abemaciclib 150 mgAbemaciclib 200 mg
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites Single Dose204 ± 70210 ± 65
SecondaryPK: Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites (Twice Daily Dosing)

PK: Maximum Concentration (Cmax) of Abemaciclib and its Metabolites following a twice daily dosing.

Time frame:
Cycle 1, Day(D) 31; Predose, 1, 2, 4, 6, 8, 10, 24 Hours Postdose
Reported as:
Geometric mean · ng/mL
PK: Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites (Twice Daily Dosing)
ng/mLAbemaciclib 100 mgAbemaciclib 150 mgAbemaciclib 200 mg
PK: Maximum Concentration (Cmax) of Abemaciclib and Its Metabolites (Twice Daily Dosing)205 ± 64267 ± 71320 ± 91
SecondaryPK: Area Under Concentration Time Curve (AUC) From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites Single Dose

PK: Area Under Concentration Time Curve (AUC) from Time Zero to 12 hours (AUC \[0-12\]) of Abemaciclib and its Metabolites following a single oral dose.

Time frame:
Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
PK: Area Under Concentration Time Curve (AUC) From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites Single Dose
nanogram*hour/milliliter (ng*hr/mL)Abemaciclib 150 mgAbemaciclib 200 mg
PK: Area Under Concentration Time Curve (AUC) From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites Single Dose1700 ± 751740 ± 68
SecondaryPK: AUC From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites (Twice Daily Dosing)

PK: AUC from Time Zero to 12 hours (AUC \[0-12\]) of Abemaciclib and its Metabolites following twice daily dosing

Time frame:
Cycle 1, Day(D) 31; Predose, 1, 2, 4, 6, 8, 10, 24 Hours Postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites (Twice Daily Dosing)
ng*hr/mLAbemaciclib 100 mgAbemaciclib 150 mgAbemaciclib 200 mg
PK: AUC From Time Zero to 12 Hours (AUC [0-12]) of Abemaciclib and Its Metabolites (Twice Daily Dosing)2190 ± 652770 ± 733270 ± 101
SecondaryPK: AUC From Time Zero to Infinity (AUC[0-inf]) of Abemaciclib and Its Metabolites Single Dose

PK: AUC from Time Zero to Infinity (AUC\[0-inf\]) of Abemaciclib and its Metabolites following a single oral dose.

Time frame:
Cycle 1, Day(D)1; Predose, 1, 4, 6, 8, 10, 24, 48 Hours Postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC From Time Zero to Infinity (AUC[0-inf]) of Abemaciclib and Its Metabolites Single Dose
ng*hr/mLAbemaciclib 150 mgAbemaciclib 200 mg
PK: AUC From Time Zero to Infinity (AUC[0-inf]) of Abemaciclib and Its Metabolites Single Dose6790 ± 637580 ± 74
SecondaryObjective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

ORR was defined as the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum LD of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

Time frame:
Baseline to Measured Progressive Disease (Up to 13 Months )
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
percentage of participantsAbemaciclib 150 mgAbemaciclib 200 mg
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)8.3 (0.2 to 38.5)7.7 (0.2 to 36.0)

Adverse events

Collected over Up to 10 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib 150 mg6/12 (50%)2/12 (16.7%)12/12 (100%)
Abemaciclib 200 mg1/13 (7.7%)4/13 (30.8%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventAbemaciclib 150 mgAbemaciclib 200 mg
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/123/13
AnaemiaBlood and lymphatic system disorders1/120/13
PneumoniaInfections and infestations1/120/13
Alanine aminotransferase increasedInvestigations1/120/13
Platelet count decreasedInvestigations1/120/13
Respiratory failureRespiratory, thoracic and mediastinal disorders1/120/13
Urinary tract infectionInfections and infestations0/121/13
Most frequent other events
Showing 10 of 74
Most frequent other events
EventAbemaciclib 150 mgAbemaciclib 200 mg
DiarrhoeaGastrointestinal disorders9/1211/13
Decreased appetiteMetabolism and nutrition disorders10/126/13
Neutrophil count decreasedInvestigations9/128/13
White blood cell count decreasedInvestigations8/126/13
Blood creatinine increasedInvestigations6/128/13
MalaiseGeneral disorders7/126/13
AnaemiaBlood and lymphatic system disorders6/125/13
NauseaGastrointestinal disorders3/126/13
CoughRespiratory, thoracic and mediastinal disorders5/124/13
Platelet count decreasedInvestigations4/125/13

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Abemaciclib 150 mgAbemaciclib 200 mgTotal
Mean55.58 ± 11.4752.00 ± 8.7653.72 ± 10.10
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib 150 mgAbemaciclib 200 mgTotal
Female111122
Male123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib 150 mgAbemaciclib 200 mgTotal
Hispanic or Latino000
Not Hispanic or Latino000
Unknown or Not Reported121325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib 150 mgAbemaciclib 200 mgTotal
American Indian or Alaska Native000
Asian121325
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib 150 mgAbemaciclib 200 mgTotal
China121325
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410013, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, China
09

References and documents

Publications

  • Zhang J, Yang N, Ji D, Shen W, Li W, Han R, Wang N, Tao H, Chapman SC, Sykes AK, Zhang W, Hu X. A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. Target Oncol. 2021 Mar;16(2):177-187. doi: 10.1007/s11523-020-00789-9. Epub 2021 Jan 25. PubMed 33492568 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Nov 2018, 15 months.

Results were first posted in Sep 2020, 1 year 10 months after primary completion.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 15 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Sep 29, 2016
StartActual
Aug 7, 2017
Primary completionActual
Nov 23, 2018
CompletionActual
Sep 3, 2019
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02919696
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Aug 7, 2017
Primary completion
Nov 23, 2018
Completion
Sep 3, 2019
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion